Arexvy (GSK) is stored in the refrigerator and is available in two presentations: a vial of lyophilized antigen (powder) paired with either a vial or a prefilled syringe of adjuvant suspension (liquid). Reconstitute only with the supplied adjuvant component. Both the liquid and the powder should be stored refrigerated between 2°C and 8°C (36°F and 46°F) in the original package in order to protect the components from light. Do not freeze. Discard if either component has been frozen.
After reconstitution, administer immediately or store in the refrigerator between 2°C and 8°C (36°F to 46°F) or at room temperature (defined for this vaccine as up to 25°C [77°F]) for up to 4 hours before use. Discard reconstituted vaccine if not used within 4 hours. See the current package insert: https://www.fda.gov/media/167805/download.
Last reviewed:
November 8, 2026
The mRNA RSV vaccine (mResvia, Moderna) is supplied as a manufacturer-filled syringe (MFS) that contains a frozen suspension that must be thawed before administration either in the refrigerator or at room temperature. Vaccine should not be refrozen once thawed. Do not shake any mRNA vaccine because shaking can damage the potency of the vaccine by breaking up the small bubbles of fat (lipid) that contain the mRNA.
- Freezer storage: The frozen vaccine in the plastic MFS can be stored in the freezer between -40°C to -15°C (-40°F to 5°F) until the expiration date printed on its packaging.
- Refrigerator storage: The thawed plastic MFS may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 90 days before being used, or until its labeled expiration date, whichever comes first. If stored in the refrigerator, place a label on the vaccine indicating when it was placed in the refrigerator and its ‘use by date’, which is 90 days later. Discard an MFS that has been in the refrigerator beyond its 90-day use-by date.
- Room temperature storage: The thawed plastic MFS may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours after removal from refrigerated conditions. Discard the MFS if not used within this time. Do not return an MFS to the refrigerator after it has been thawed at room temperature.
- Refer to the mResvia package insert for specific instructions and additional details on storage and thawing: fda.gov/media/179005/download. Follow the current label for the presentation; the label specifies the need to protect the vaccine from direct sunlight and ultraviolet light. Never use beyond the expiration date.
Last reviewed:
November 8, 2026
Nirsevimab (Beyfortus, Sanofi) comes in two single-dose manufacturer-filled syringe (MFS) formulations: 50-mg and 100-mg. Nirsevimab should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). It may be kept at room temperature 68°F to 77°F (20°C to 25°C) for a maximum of 8 hours. After removal from the refrigerator, nirsevimab must be used within 8 hours or discarded. Store nirsevimab in the original carton to protect it from light until time of use. Do not freeze. Do not shake. Do not expose to heat.
Last reviewed:
November 8, 2026
Clesrovimab (Enflonsia, Merck) comes in a manufacturer-filled syringe (MFS) as a 105-mg, 0.7 mL dose. The MFS should be refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light until time of use.
Clesrovimab may be kept at room temperature between 68°F to 77°F (20°C to 25°C) for a maximum of 48 hours. After removal from the refrigerator, it must be used within 48 hours or discarded.
Clesrovimab should not be used if frozen. The MFS should not be shaken.
Last reviewed:
November 8, 2026
No. Seasonal influenza vaccines are reformulated each year; for this reason, all unused seasonal influenza vaccines expire and should be discarded no later than the end of June each season. RSV products (vaccines and preventive antibody) do not change each season and products in your storage unit now may not expire until sometime during or after the next season.
Properly store and clearly label unexpired products remaining in your storage unit during periods when they are not in use and train staff on the timing of these products, especially for vaccination during pregnancy and use of RSV preventive antibody products. Consider storage and labeling that minimizes the risk of mishandling or administration outside the times when the product is recommended to be used.
Last reviewed:
November 8, 2026
Last reviewed:
December 6, 2024